Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk Hospitalization 35% c19hcq.org Mokhtari et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 28,759 patients in Iran Lower mortality (p<0.0001) and hospitalization (p<0.0001) Mokhtari et al., Int. Immunopharmacology, doi:10.1016/j.intimp.2021.107636 Favors HCQ Favors control
Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting
Mokhtari et al., International Immunopharmacology, doi:10.1016/j.intimp.2021.107636
Mokhtari et al., Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient.., International Immunopharmacology, doi:10.1016/j.intimp.2021.107636
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 28,759 adult outpatients with mild COVID-19 in Iran, 7,295 treated with HCQ, showing significantly lower hospitalization and mortality with treatment.
risk of death, 69.7% lower, RR 0.30, p < 0.001, treatment 27 of 7,295 (0.4%), control 287 of 21,464 (1.3%), NNT 103, adjusted per study, odds ratio converted to relative risk.
risk of hospitalization, 35.3% lower, RR 0.65, p < 0.001, treatment 523 of 7,295 (7.2%), control 2,382 of 21,464 (11.1%), NNT 25, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mokhtari et al., 6 Apr 2021, retrospective, Iran, peer-reviewed, 11 authors, dosage 400mg bid day 1, 200mg bid days 2-5.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. International Immunopharmacology 96 (2021) 107636 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting Majid Mokhtari a, Minoo Mohraz b, Mohammad Mehdi Gouya c, Hengameh Namdari Tabar d, Jafar-Sadegh Tabrizi l, Katayoun Tayeri e, Saeide Aghamohamadi f, Zahra Rajabpoor g, Manoochehr Karami h, Alireza Raeisi i, Hamid Rahmani j, Hossein Khalili k, * a Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran Center for Communicable Disease Control (CDC), IHR National Focal Point, Ministry of Health & Medical Education, Tehran, Iran d Ministry of Health and Medical Education, AIDS/STI Control Dep. Ministry of Health and Medical Education, Eyvanak Street, Shahrak-e-Gharb, Tehran, Iran e Ministry of Health and Medical Education, Tehran Iran, Eyvanak Street, Shahrak-e-Gharb, Tehran, Iran f Health Service Management, Deputy of Health, Ministry of Health and Medical Education, Tehran, Iran g Ministry of Health and Medical Education, Eyvanak Street, Shahrak-e-Gharb, Tehran, Iran h Research Center for Health Sciences, Hamadan University of Medical Sciences, Hamadan, Iran i School of Medicine, Shiraz University of Medical Sciences, Shiraz Iran, Deputy of Health, Ministry of Health and Medical Education, Tehran, Iran j Department of Pharmacotherapy, Tehran University of Medical Sciences, Tehran, Iran k Department of Pharmacotherapy, Tehran University of Medical Sciences, Postal Code: 1417614411, P.O. Box: 14155/6451, Tehran, Iran l Tabriz Health Services Management Research Center, Tabriz, Iran b c A R T I C L E I N F O A B S T R A C T Keywords: COVID-19 Outpatient Hydroxychloroquine The role of hydroxychloroquine (HCQ) in early outpatient management of mild coronavirus disease 2019 (COVID-19) needs further investigation. This study was a multicenter, population-based national retrospective-cohort investigation of 28,759 adults with mild COVID-19 seen at the network of Comprehensive Healthcare Centers (CHC) between March and September 2020 throughout Iran. The baseline characteristics and outcome variables were extracted from the national integrated health system database. A total of 7295 (25.37%) patients who presented with mild COVID-19 within 3–7 days of symptoms onset received HCQ (400 mg twice daily on day 1 followed by 200 mg twice daily for the next four days and were then followed for 14 days). The main outcome..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit